Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Neil A. O’Brien(APLA Health), Dennis J. Slamon(University of California, Los Angeles)

Breast Cancer Research

August 14, 2020

10.1186/s13058-020-01320-8

Cited by 155

Related Papers

Palbociclib and Letrozole in Advanced Breast Cancer

|New England Journal of Medicine|2016|2.9k

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

|New England Journal of Medicine|2018|1.3k

Frequent Mutations of Chromatin Remodeling Gene <i>ARID1A</i> in Ovarian Clear Cell Carcinoma

|Science|2010|1.2k

Cycling cancer persister cells arise from lineages with distinct programs

|Nature|2021|514